Baker Bros. Advisors LP Bicycle Therapeutics PLC Transaction History
Baker Bros. Advisors LP
- $7.52 Billion
- Q2 2024
A detailed history of Baker Bros. Advisors LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Baker Bros. Advisors LP holds 9,399,960 shares of BCYC stock, worth $213 Million. This represents 2.53% of its overall portfolio holdings.
Number of Shares
9,399,960
Previous 4,942,823
90.17%
Holding current value
$213 Million
Previous $123 Million
54.58%
% of portfolio
2.53%
Previous 1.56%
Shares
4 transactions
Others Institutions Holding BCYC
# of Institutions
112Shares Held
41.1MCall Options Held
3.4KPut Options Held
12.4K-
Deep Track Capital, LP Greenwich, CT3.49MShares$79.3 Million2.32% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$51.2 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.12MShares$48.2 Million6.34% of portfolio
-
Armistice Capital, LLC New York, NY1.97MShares$44.8 Million0.52% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.52MShares$34.6 Million0.16% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $674M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...